澳门巴黎人娱乐

transition
silde-l

International technology group integrating R & D, production and sales.

  • Overview
  • Financial Highlights
  • Financial Report
  • Announcement & Circular
  • Investor Presentation
  • Press Release
  • Investor Event
  • Analysts Coverage
  • Prospectus
  • Stock Information
  • Policy and Contact

Overview

Financial Report +MORE

Press Release +MORE

Announcement & Circular +MORE

Investor Event +MORE

Investor Presentation +MORE

Financial Highlights

Results

For the ended 31 December

(RMB’000) 2014 2013 2012 2011 2010
Turnover 864,621 754,115 739,132 2,758,152 2,667,978
Gross Profit 391,341 288,968 271,819 890,646 663,203
Profit(loss) from operations 96,071 (577,638) (1,117,190) 365,552 255,537
Profit (loss) before taxation 17,327 (652,841) (1,177,288) 307,469 210,158
Profit (loss) for the year 2,087 (673,458) (1,109,316) 234,377 129,410

Assets and Liabilities

At 31 December

(RMB’000) 2014 2013 2012 2011 2010
Total non-current assets 437,554 374,591 397,671 320,073 288,076
Total current assets 1,047,878 1,067,055 1,827,321 3,250,963 2,467,260
Total current liabilities 1,129,621 922,035 1,318,945 1,514,494 2,250,398
Net current (liabilities) assets (81,743) 145,020 508,376 1,736,469 216,862
Total assets less current liabilities 355,811 519,611 906,047 2,056,542 504,938
Total non-current liabilities 142,832 310,812 21,053 1,235 2,661
Net assets 212,979 208,799 884,994 2,055,307 502,277
Total equity attributable to equity shareholders of the Company 212,979 208,799 884,994 2,040,177 487,147

Financial Report


YEAR

REPORT TYPE


Announcement & Circular

  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011

Investor Presentation

  • 2018
  • 2016
  • 2015

Press Release

  • 2018
  • 2016
  • 2015

Investor Event

内容更新中...

Prospectus

Prospectus

Stock Information

NT PHARMA (01011.HK)

%)

(Beijing time)

Shanghai Composite Index: ( %)

Shenzhen Component Index: ( %)

  • Open
  • Prev Close
  • Highest
  • Lowest
  • Volume
  • P/E Ratio

Policy and Contact

  • IR Policy and Contact

    NT Pharma attaches great importance to corporate transparency and timely provides relevant information for shareholders. As a listed company (01011.HK) in main board of Hong Kong Exchanges and Clearing Limited, NT Pharma focuses on maintaining a high corporate transparency and governance level. It also tries to enable parties to know its business development strategy and growth potential better, by actively communicating with the investment market.
    In this aspect, Corporate Financing and Investor Relations Department has established a series of systematic communication channels, so as to provide periodical and reliable information process for shareholders, investors and analysts. The webpage for investor relations of NT Pharma will be updated regularly, to show the updated information to the public and investors. Meanwhile, we also regularly organize timely exchange activities, including telephone conference, senior management’s meeting, a visit to any project, the participation in investment forums of securities companies, road show and seminar, to keep communication with investment community and market.
    We believe that to maintain good and open relationships with media, analysts and investors is helpful to improve our market recognition and information transparency. Moreover, we avoid disclosing relevant information to some persons before making inside information public.
    NT Pharma discloses information based on this principle, that is, it only interprets public information in the market to investors and basically discusses corporate business development. We avoid responding to any single or accumulative unpublished or possible inside information consultation by any individual.

  • The comments of NT Pharma on Analysts Report are limited to:

    (a) The published basic information

    (b) Putting forward corrections on factual errors and assumptions according to the published information

    According to the listing rules in Hong Kong, a quiet period is from 30 days before interim results of half a year and others to the publication date of such results, while the quiet period for publication of annual results is 60 days. Therefore, NT Pharma will not make any comment and forecast for financial performance at any interview or meeting during the quiet period.


  • Investor and media queries:

    Corporate financing and investor relations

    E-mail:ir@ntpharma.com


  • Hong Kong

    Tel.:(852) 2808 1606

    Fax:(852) 2508 9459

    Address: Room 1505, 15/F, Bank of East Asia Harbour View Center, No. 56, Gloucester Road, Wanchai, Hong Kong